Q-omics provides the consensus-scored LRRC41 profile across patient tissues and cancer cell-line models. LRRC41 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LRRC41 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LRRC41 protein abundance shows 31,397 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where LRRC41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC41 survival associations across molecular data types. LRRC41 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC41 RNA expression–survival associations across cancer types. High LRRC41 expression shows unfavorable associations in ACC, LIHC, KIRP, LGG, CESC and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LRRC41 RNA expression.
This table summarizes LRRC41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC41 shows lower tumor expression in KICH and higher tumor expression in KIRC, LUAD, HNSC, LIHC and LUSC. The KIRC box plot shows higher LRRC41 RNA expression in tumor versus normal tissue (log2 FC = +1.020, t-test p < 0.001).
This table shows molecular features associated with LRRC41 in patient tissues and cancer cell lines. In patient samples, LRRC41 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC41 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
